摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-甲基吡啶-2-硼酸 | 372963-49-0

中文名称
5-甲基吡啶-2-硼酸
中文别名
5-甲基吡啶-2-基硼酸
英文名称
(5-methylpyridin-2-yl)boronic acid
英文别名
5-Methylpyridine-2-boronic acid
5-甲基吡啶-2-硼酸化学式
CAS
372963-49-0
化学式
C6H8BNO2
mdl
MFCD00674179
分子量
136.946
InChiKey
VDRIXWWGBDNWCM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    86-90
  • 沸点:
    314.6±44.0 °C(Predicted)
  • 密度:
    1.18±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.49
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    53.4
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36/37/39
  • 危险类别码:
    R36/37/38
  • 危险性防范说明:
    P261,P264,P271,P280,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501
  • 危险性描述:
    H315,H319,H335

SDS

SDS:7fc346c04ab4b94e1076c4072ff903b4
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5-Methylpyridine-2-boronic acid
Synonyms: 5-Methylpyridin-2-ylboronic acid; 5-Methyl-2-pyridineboronic acid

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

Section 3. Composition/information on ingredients.
Ingredient name: 5-Methylpyridine-2-boronic acid
CAS number: 372963-49-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H8BNO2
Molecular weight: 136.9

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    5-甲基吡啶-2-硼酸 在 palladium diacetate 、 potassium carbonate三苯基膦 作用下, 以 甲醇乙二醇乙醚乙腈 为溶剂, 反应 24.0h, 生成
    参考文献:
    名称:
    ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME
    摘要:
    由公式1表示的一个有机金属化合物:M(L1)n1(L2)n2公式1在公式1、2A和2B中,基团和取代基与说明书中披露的相同。
    公开号:
    US20160268521A1
点击查看最新优质反应信息

文献信息

  • PHARMACEUTICAL COMPOSITION AND THE USE THEREOF, AND APPLICATION REGIME OF SAID PHARMACEUTICAL COMPOSITION FOR ON-DEMAND CONTRACEPTION
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US20160089364A1
    公开(公告)日:2016-03-31
    The invention relates to a pharmaceutical composition for non-hormonal, on-demand contraception and to processes for preparing this pharmaceutical composition. The latter comprises 2H-indazole as novel EP2 receptor antagonists in combination with COX inhibitors. The invention furthermore provides a method for non-hormonal female-controlled on-demand contraception where a pharmaceutical composition comprising EP2 receptor antagonists in combination with COX inhibitors is taken on demand prior to expected sexual intercourse.
    这项发明涉及一种用于非激素、按需避孕的药物组合物,以及制备该药物组合物的方法。后者包括2H-吲哚唑作为新型EP2受体拮抗剂,与COX抑制剂结合使用。该发明还提供了一种非激素女性控制的按需避孕方法,其中在预期性交前按需服用含有EP2受体拮抗剂与COX抑制剂的药物组合物。
  • [EN] DIHYDROOXADIAZINONES<br/>[FR] DIHYDROOXADIAZINONES
    申请人:BAYER AG
    公开号:WO2019025562A1
    公开(公告)日:2019-02-07
    The present invention provides dihydrooxydiazinone compounds of general formula (I) : in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    本发明提供了一般式(I)的二氢氧二氮酮化合物:其中R1、R2、R3和R4如本文所定义,制备所述化合物的方法,用于制备所述化合物的中间体化合物,包含所述化合物的药物组合物和组合物,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是治疗或预防过度增殖性疾病,作为唯一药剂或与其他活性成分组合使用。
  • [EN] HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS<br/>[FR] PIPÉRIDINES HALOSUBSTITUÉES EN TANT QUE MODULATEURS DE RÉCEPTEUR DES OREXINES
    申请人:ASTRAZENECA AB
    公开号:WO2017139603A1
    公开(公告)日:2017-08-17
    The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
    本申请涉及某些含卤代哌啶化合物、含有它们的药物组合物,以及使用它们的方法,包括用于治疗物质成瘾、恐慌障碍、焦虑、创伤后应激障碍、疼痛、抑郁、季节性情感障碍、进食障碍或高血压的方法。
  • [EN] SUBSTITUTED AZA COMPOUNDS AS IRAK-4 INHIBITORS<br/>[FR] COMPOSÉS AZA SUBSTITUÉS COMME INHIBITEURS DE L'IRAK-4
    申请人:AURIGENE DISCOVERY TECH LTD
    公开号:WO2017009806A1
    公开(公告)日:2017-01-19
    The present invention provides substituted aza compounds of formula (I) or (II) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK-4 and/or for the treatment of diseases or disorders induced by IRAK-4.
    本发明提供了式(I)或(II)的取代氮杂化合物及其在药学上可接受的盐,并且它们用于抑制IRAK-4和/或治疗由IRAK-4引起的疾病或紊乱。
  • Photoredox/Nickel Dual Catalysis Enables the Synthesis of Alkyl Cyclopropanes via C(sp<sup>3</sup>)–C(sp<sup>3</sup>) Cross Electrophile Coupling of Unactivated Alkyl Electrophiles
    作者:Sayan K. Jana、Mamata Maiti、Purusattam Dey、Biplab Maji
    DOI:10.1021/acs.orglett.1c04268
    日期:2022.2.18
    cyclopropanes via visible light-mediated photoredox/nickel dual catalysis is demonstrated. The challenging intramolecular C(sp3)–C(sp3) cross-electrophile coupling of readily available unactivated 1,3-dialkyl electrophiles was performed under mild conditions that allowed traditionally reactive functional groups to be included. Mechanistic inspection and control experiments revealed the importance of dual catalysis
    展示了通过可见光介导的光氧化还原/镍双重催化轻松合成单、1,1-和 1,2-二取代环丙烷。具有挑战性的分子内 C(sp 3 )–C(sp 3 ) 交叉亲电偶联容易获得的未活化的 1,3-二烷基亲电试剂是在温和条件下进行的,该条件允许包含传统的反应性官能团。机械检查和控制实验揭示了双重催化的重要性,反应通过逐步氧化加成和分子内 S N 2 反应进行。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-